Jasper Therapeutics
JSPR
28 hedge funds and large institutions have $62.5M invested in Jasper Therapeutics in 2020 Q1 according to their latest regulatory filings, with 28 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCAM
Owl Creek Asset Management
New York
|
+$8.42M |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$5.87M |
| 3 |
TCM
Tenor Capital Management
New York
|
+$4.89M |
| 4 |
GCL
Glazer Capital LLC
New York
|
+$4.66M |
| 5 |
SRCM
Sage Rock Capital Management
New York
|
+$3.98M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SCM
26
Shaolin Capital Management
Miami,
Florida
| $261K | +$269K | +2,750 | New |
|
|
MAM
27
Marquette Asset Management
Minneapolis,
Minnesota
| $129K | +$133K | +1,355 | New |
|
28
UBS Group
Zurich,
Switzerland
| $13K | +$13.7K | +140 | New |
|
JSPR Hedge Fund Activity: Q1 2020 in Review
28 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q1 2020, worth a combined $62.5M.
Buyers outnumbered sellers: 28 funds opened new JSPR positions and 0 closed out — a net gain of 28 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Owl Creek Asset Management, opening a new position worth an estimated $8.42M.
- 28 institutional investors held Jasper Therapeutics (JSPR) as of Q1 2020, up from 0 in Q4 2019.
- Funds reported $62.5M of Jasper Therapeutics stock for Q1 2020.
- 28 funds opened new Jasper Therapeutics positions in Q1 2020 and 0 closed out, a net change of +28 holders.
- The largest Jasper Therapeutics buyer in Q1 2020 was Owl Creek Asset Management, an estimated $8.42M added.
Based on aggregated 13F filings for Q1 2020.